{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:54:59Z","timestamp":1791057299061,"version":"4.1.0"},"reference-count":168,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M781926"],"award-info":[{"award-number":["2025M781926"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015796","name":"Shanghai Lingjun Program","doi-asserted-by":"publisher","award":["24YF2704100"],"award-info":[{"award-number":["24YF2704100"]}],"id":[{"id":"10.13039\/100015796","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503587"],"award-info":[{"award-number":["82503587"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473184"],"award-info":[{"award-number":["82473184"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbcan.2026.189709","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:22:29Z","timestamp":1789168949000},"page":"189709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment"],"prefix":"10.1016","volume":"1881","author":[{"given":"Xinran","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junkan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongwu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2026.189709_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2026.189709_bb0010","article-title":"Siegel - 2025","author":"Cancer Statistics","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2026.189709_bb0015","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.bbcan.2026.189709_bb0020","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.2010.32.6181","article-title":"Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas","volume":"29","author":"D\u2019Angelo","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0025","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/JTO.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1342086","article-title":"NSCLC: from tumorigenesis, immune checkpoint misuse to current and future targeted therapy","volume":"15","author":"Raskova Kafkova","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0035","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.jtho.2025.05.024","article-title":"Advances in lung Cancer basic and translational research in 2025 \u2013 overview and perspectives focusing on NSCLC","volume":"20","author":"Mascaux","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202505785","article-title":"EGFR: new insights on its activation and mutation in tumor and tumor immunotherapy","volume":"12","author":"Gu","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bbcan.2026.189709_bb0045","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0777-1","article-title":"Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.bbcan.2026.189709_bb0050","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/cac2.12594","article-title":"Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)","volume":"44","author":"Lu","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.bbcan.2026.189709_bb0055","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231192396","article-title":"Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma","volume":"15","author":"C\u00e1rdenas-Fern\u00e1ndez","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0060","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with Osimertinib in untreated, EGFR -mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189709_bb0070","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of Aumolertinib versus Gefitinib as first-line therapy for locally advanced or MetastaticNon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0075","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.bbcan.2026.189709_bb0080","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S2213-2600(23)00183-2","article-title":"Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.bbcan.2026.189709_bb0085","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1200\/JCO.23.00515","article-title":"Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301","volume":"41","author":"Cho","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2026.108107","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 update","volume":"224","author":"Roskoski","year":"2026","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105583","article-title":"EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: from molecular mechanisms to clinical research","volume":"167","author":"Dong","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nature17960","article-title":"Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors","volume":"534","author":"Jia","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2026.189709_bb0105","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1080\/07391102.2020.1734092","article-title":"In silico search of triple mutant T790M\/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation","volume":"39","author":"Patel","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bbcan.2026.189709_bb0110","first-page":"402","article-title":"An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer","volume":"3","author":"To","year":"2022","journal-title":"Nat. Can."},{"key":"10.1016\/j.bbcan.2026.189709_bb0115","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221146131","article-title":"Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations","volume":"15","author":"Low","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0120","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.3390\/ijms25115917","article-title":"Targeted therapies for EGFR exon 20 insertion mutation in non-small-cell lung cancer","volume":"25","author":"Seo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2026.189709_bb0125","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e20652","article-title":"A real-world study on first-line (1L) treatment for 46 advanced lung adenocarcinoma patients harbouring epidermal growth factor 20 insertion mutation (EGFR ex20ins)","volume":"43","author":"Tian","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107465","article-title":"Targeted and cytotoxic inhibitors used in the treatment of lung cancers","volume":"209","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0135","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.lungcan.2022.05.011","article-title":"Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: focus on novel therapies","volume":"170","author":"Johnson","year":"2022","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bbcan.2026.189709_bb0140","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","article-title":"Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer","volume":"61","author":"Harrison","year":"2020","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0145","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/cac2.12627","article-title":"Cancer situation in China: an analysis based on the global epidemiological data released in 2024","volume":"45","author":"Diao","year":"2025","journal-title":"Cancer Commun."},{"key":"10.1016\/j.bbcan.2026.189709_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107123","article-title":"PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: clinical challenges and opportunities","volume":"202","author":"Liu","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0155","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cac2.12505","article-title":"Management of locally advanced non-small cell lung cancer: state of the art and future directions","volume":"44","author":"Miao","year":"2024","journal-title":"Cancer Commun."},{"key":"10.1016\/j.bbcan.2026.189709_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.108066","article-title":"Antibody-drug conjugates: a new twist to overcome EGFR-TKIs resistance in non-small cell lung cancer","volume":"223","author":"Deng","year":"2026","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0165","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41577-025-01207-9","article-title":"Fifty years of monoclonals: the past, present and future of antibody therapeutics","volume":"25","author":"Chan","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102902","article-title":"Antibody-drug conjugates in NSCLC with actionable genomic alterations: optimizing smart delivery of chemotherapy to the target","volume":"134","author":"Mountzios","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2026.189709_bb0175","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.clinthera.2005.06.003","article-title":"Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer","volume":"27","author":"Wong","year":"2005","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bbcan.2026.189709_bb0180","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","article-title":"Structural basis for inhibition of the epidermal growth factor receptor by cetuximab","volume":"7","author":"Li","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2026.189709_bb0185","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/1078-0432.CCR-06-1726","article-title":"Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines","volume":"13","author":"Kurai","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0190","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/j.ejca.2012.01.007","article-title":"Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer","volume":"48","author":"Rodr\u00edguez","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189709_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2009.03992.x","article-title":"Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy","volume":"158","author":"Martinelli","year":"2009","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0200","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1158\/1535-7163.MCT-18-0341","article-title":"Immune effector functions of human IgG2 antibodies against EGFR","volume":"18","author":"R\u00f6sner","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189709_bb0205","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa074943","article-title":"Cetuximab-induced anaphylaxis and IgE specific for galactose-\u03b1-1,3-galactose","volume":"358","author":"Chung","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189709_bb0210","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4161\/cbt.11.4.14097","article-title":"Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile","volume":"11","author":"Garrido","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bbcan.2026.189709_bb0215","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/14712598.2018.1452906","article-title":"Cetuximab for treating non-small cell lung cancer","volume":"18","author":"Mazzarella","year":"2018","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.bbcan.2026.189709_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110001","article-title":"EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: a systematic review and meta-analysis","volume":"119","author":"Liu","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102664","article-title":"The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer","volume":"122","author":"Ciardiello","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2026.189709_bb0230","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2008.18.9670","article-title":"Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma","volume":"27","author":"Pan","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0235","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.biopha.2017.02.097","article-title":"A randomized phase III study of combining erlotinib with bevacizumab and panitumumab versus erlotinib alone as second-line therapy for Chinese patients with non-small-cell lung cancer","volume":"89","author":"Wang","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbcan.2026.189709_bb0240","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1021\/acs.molpharmaceut.4c00823","article-title":"Immuno-PET imaging of EGFR with 64Cu-NOTA Panitumumab in subcutaneous and metastatic nonsmall cell lung Cancer xenografts","volume":"21","author":"Sarrami","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbcan.2026.189709_bb0245","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1200\/JCO.2004.03.089","article-title":"Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients","volume":"22","author":"Crombet","year":"2004","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0250","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/1078-0432.CCR-15-1653","article-title":"A phase Ib\/II study of afatinib in combination with nimotuzumab in non-small cell lung cancer patients with acquired resistance to gefitinib or erlotinib","volume":"22","author":"Lee","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0255","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.cllc.2020.12.012","article-title":"Phase 2 study of Nimotuzumab in combination with concurrent chemoradiotherapy in patients with locally advanced non\u2013small-cell lung cancer","volume":"22","author":"Yamamoto","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bbcan.2026.189709_bb0260","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ijrobp.2021.06.032","article-title":"Concurrent chemoradiation therapy with or without Nimotuzumab in locally advanced squamous cell lung cancer: a phase 2 randomized trial","volume":"111","author":"Qiu","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbcan.2026.189709_bb0265","first-page":"1434","article-title":"Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer","volume":"11","author":"Dienstmann","year":"2010","journal-title":"Curr. Opin. Investig. Drugs (Lond. Engl.)"},{"key":"10.1016\/j.bbcan.2026.189709_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01249","article-title":"The latest battles between EGFR monoclonal antibodies and resistant tumor cells","volume":"10","author":"Cai","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0275","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial","volume":"16","author":"Thatcher","year":"2015","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2026.189709_bb0280","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1200\/JCO.2019.37.15_suppl.9057","article-title":"Osimertinib (Osi) plus necitumumab (Neci) in EGFR-mutant NSCLC: an ETCTN California cancer consortium phase I study","volume":"37","author":"Riess","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2026.189709_bb0285","doi-asserted-by":"crossref","first-page":"9014","DOI":"10.1200\/JCO.2022.40.16_suppl.9014","article-title":"Osimertinib plus necitumumab in EGFR-mutant NSCLC: final results from an ETCTN California Cancer consortium phase I study","volume":"40","author":"Riess","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0290","article-title":"An anti-EGFR antibody, necitumumab, suppresses emergence of osimertinib-resistant clones from EGFR L858R NSCLC cells","volume":"82nd","author":"Naoyuki","year":"2023","journal-title":"\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a\u6284\u9332\u96c6 (Web)"},{"key":"10.1016\/j.bbcan.2026.189709_bb0295","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s10637-021-01099-1","article-title":"Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers","volume":"39","author":"Hou","year":"2021","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.bbcan.2026.189709_bb0300","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.1038\/s41467-023-39139-4","article-title":"Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer","volume":"14","author":"Zhao","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189709_bb0305","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab\u2013FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189709_bb0310","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1470-2045(11)70318-7","article-title":"EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study","volume":"13","author":"Pirker","year":"2012","journal-title":"Lancet Oncol."},{"issue":"6_Supplement","key":"10.1016\/j.bbcan.2026.189709_bb0315","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1158\/1538-7445.AM2024-2355","article-title":"Abstract 2355: SGN-EGFRd2 binding and activity are agnostic to common EGFR extracellular resistance mutations acquired in response to anti-EGFR targeted antibody therapies","volume":"84","author":"Nguyen","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0320","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26083594","article-title":"Experimental system design and modelling of EGFR extracellular domain and its mutant binding to antibody interacting partner","volume":"26","author":"Erdemir","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189709_bb0325","first-page":"328","article-title":"Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies","volume":"40","author":"Zhou","year":"2021","journal-title":"J. Exp. Clin. Cancer Res. CR."},{"key":"10.1016\/j.bbcan.2026.189709_bb0330","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S1470-2045(10)70130-3","article-title":"Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis","volume":"11","author":"De Roock","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0335","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-019-0259-4","article-title":"Microenvironment plasticity confers cetuximab resistance","volume":"16","author":"Sidaway","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0340","doi-asserted-by":"crossref","first-page":"511","DOI":"10.5966\/sctm.2015-0214","article-title":"Cancer stem cell-based models of colorectal cancer reveal molecular determinants of therapy resistance","volume":"5","author":"De Angelis","year":"2016","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.bbcan.2026.189709_bb0345","doi-asserted-by":"crossref","first-page":"5942","DOI":"10.1158\/0008-5472.CAN-10-0157","article-title":"The epidermal growth factor receptor antibody Cetuximab induces autophagy in cancer cells by downregulating HIF-1\u03b1 and Bcl-2 and activating the Beclin 1\/hVps34 complex","volume":"70","author":"Li","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0350","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.canlet.2017.03.023","article-title":"Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer","volume":"396","author":"Koustas","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2026.189709_bb0355","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41571-023-00815-5","article-title":"Drug-tolerant persister cells in cancer: the cutting edges and future directions","volume":"20","author":"Pu","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0360","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bcp.2018.11.004","article-title":"Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer","volume":"162","author":"Vallette","year":"2019","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0365","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2020.10.027","article-title":"Persistent cancer cells: the deadly survivors","volume":"183","author":"Shen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2026.189709_bb0370","article-title":"Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer","volume":"2014","author":"Yang","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bbcan.2026.189709_bb0375","article-title":"Bispecific antibodies: from research to clinical application","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0380","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S1470-2045(15)00039-X","article-title":"Multifunctional receptor-targeting antibodies for cancer therapy","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0385","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/s41571-024-00905-y","article-title":"Bispecific and multispecific antibodies in oncology: opportunities and challenges","volume":"21","author":"Goebeler","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0390","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbcan.2026.189709_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100641","article-title":"Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET","volume":"296","author":"Neijssen","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbcan.2026.189709_bb0400","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1158\/1535-7163.MCT-20-0071","article-title":"Amivantamab (JNJ-61186372), an Fc enhanced EGFR\/cMet bispecific antibody, induces receptor Downmodulation and antitumor activity by monocyte\/macrophage Trogocytosis","volume":"19","author":"Vijayaraghavan","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189709_bb0405","article-title":"Targeting MET in NSCLC: an ever-expanding territory","volume":"5","author":"Han","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"10.1016\/j.bbcan.2026.189709_bb0410","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","volume":"29","author":"Cho","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2026.189709_bb0415","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJMc2414705","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"392","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189709_bb0420","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01679-1","article-title":"Recent advances in therapeutic strategies for non-small cell lung cancer","volume":"18","author":"Su","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0425","doi-asserted-by":"crossref","first-page":"411","DOI":"10.18632\/oncotarget.28730","article-title":"Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib","volume":"16","author":"Kim","year":"2025","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2026.189709_bb0430","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR exon 20 insertion\u2013mutated non\u2013small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study","volume":"39","author":"Park","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0435","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA","volume":"35","author":"Felip","year":"2024","journal-title":"Ann. Oncol."},{"issue":"7_Supplement","key":"10.1016\/j.bbcan.2026.189709_bb0440","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1158\/1538-7445.AM2023-4999","article-title":"Abstract 4999: preclinical evaluation of MCLA-129, a bispecific antibody targeting EGFR and c-MET on solid tumor cells, in comparison with amivantamab","volume":"83","author":"de Gorter","year":"2023","journal-title":"Cancer Res."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2026.189709_bb0445","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1200\/JCO.2024.42.16_suppl.8604","article-title":"Efficacy and safety of MCLA-129, an EGFR\/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0450","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/1078-0432.CCR-22-2535","article-title":"A multipronged unbiased strategy guides the development of an anti-EGFR\/EPHA2\u2013bispecific antibody for combination cancer therapy","volume":"29","author":"El Zawily","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"6_Supplement","key":"10.1016\/j.bbcan.2026.189709_bb0455","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1158\/1538-7445.AM2024-1892","article-title":"Abstract 1892: KK2260: a fully human tetravalent bispecific antibody targeting TfR1 and EGFR for the treatment of EGFR-expressing tumors","volume":"84","author":"Mitamura","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0460","article-title":"Bevacizumab loaded CalliSpheres\u00ae bronchial arterial chemoembolization combined with immunotherapy and targeted therapy for advanced lung adenocarcinoma","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0465","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0470","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.pharmthera.2011.03.012","article-title":"Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis","volume":"131","author":"Larsen","year":"2011","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbcan.2026.189709_bb0475","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-08-2904","article-title":"Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance","volume":"15","author":"Naumov","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0480","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2016-5198","article-title":"Combination effect of anti-VEGFR-2 antibody with erlotinib on EGFR mutant non-small cell lung cancer","volume":"76","author":"Kayatani","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0485","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1200\/JCO.2012.47.3983","article-title":"ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer","volume":"31","author":"Johnson","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0490","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0495","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","article-title":"Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial","volume":"20","author":"Saito","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0500","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","article-title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Nakagawa","year":"2019","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2026.189709_bb0505","doi-asserted-by":"crossref","first-page":"9007","DOI":"10.1200\/JCO.2018.36.15_suppl.9007","article-title":"Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation\u2013positive non-squamous non\u2013small-cell lung cancer (NSCLC): survival follow-up results of JO25567","volume":"36","author":"Yamamoto","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0510","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"VEGF inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bbcan.2026.189709_bb0515","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0049-3848(12)70016-6","article-title":"Side effects of anti-angiogenic drugs","volume":"129","author":"Elice","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0520","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0525","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41416-018-0194-7","article-title":"Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment","volume":"119","author":"de Langen","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2026.189709_bb0530","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102902","article-title":"Antibody-drug conjugates in NSCLC with actionable genomic alterations: optimizing smart delivery of chemotherapy to the target","volume":"134","author":"Mountzios","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2026.189709_bb0535","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1200\/JCO.23.00013","article-title":"Antibody-drug conjugates in lung cancer: recent advances and implementing strategies","volume":"41","author":"Passaro","year":"2023","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0540","article-title":"Antibody-drug conjugates in lung cancer: dawn of a new era?","volume":"7","author":"Coleman","year":"2023","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0545","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.bbcan.2026.189709_bb0550","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0555","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100260","article-title":"Targeting HER2 in non-small-cell lung cancer (NSCLC): a glimpse of hope? An updated review on therapeutic strategies in NSCLC harbouring HER2 alterations","volume":"6","author":"Riudavets","year":"2021","journal-title":"ESMO Open."},{"key":"10.1016\/j.bbcan.2026.189709_bb0565","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1056\/NEJMe2119442","article-title":"Targeting HER2 -mutant NSCLC \u2014 the light is on","volume":"386","author":"Passaro","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2026.189709_bb0570","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1158\/1078-0432.CCR-18-1590","article-title":"Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non\u2013small cell lung cancer: efficacy, safety, and biomarkers","volume":"25","author":"Peters","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0575","doi-asserted-by":"crossref","first-page":"S608","DOI":"10.1016\/j.jtho.2025.09.1151","article-title":"PT2.10.04 efficacy and safety of TQB2102, a Biparatopic HER2-targeting ADC, in HER-2 aberrant NSCLC: a phase II study","volume":"20","author":"Zhang","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0580","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1472545","article-title":"Application of disitamab vedotin in the multiline treatment of EGFR mutation-positive lung adenocarcinoma with HER-2 overexpression","volume":"14","author":"Lan","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0585","article-title":"EGFR-directed antibodies promote HER2 ADC internalization and efficacy","volume":"5","author":"Gupta","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bbcan.2026.189709_bb0590","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s10637-025-01507-w","article-title":"A novel anti-HER2\/EGFR bispecific antibody-drug conjugate demonstrates promising antitumor efficacy and overcomes resistance to HER2- or EGFR-targeted ADCs","volume":"43","author":"Huang","year":"2025","journal-title":"Investig. New Drugs"},{"issue":"8_Supplement_1","key":"10.1016\/j.bbcan.2026.189709_bb0595","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1158\/1538-7445.AM2025-340","article-title":"Abstract 340: GenSci139, a highly differentiated EGFR\u00d7HER2 bispecific ADC, for the treatment of multiple solid tumors","volume":"85","author":"Chai","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0600","doi-asserted-by":"crossref","first-page":"7406","DOI":"10.1038\/s41598-019-43678-6","article-title":"EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients","volume":"9","author":"Scharpenseel","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189709_bb0605","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor\u2013mutated non\u2013small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0610","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"issue":"6_Supplement","key":"10.1016\/j.bbcan.2026.189709_bb0615","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1158\/1538-7445.AM2024-2619","article-title":"Abstract 2619: a novel EGFR \u00d7 HER3-targeting bispecific antibody drug-conjugate, BCG019, demonstrates robust anti-tumor efficacy in preclinical evaluation","volume":"84","author":"Li","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0620","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1158\/1535-7163.MCT-07-2003","article-title":"Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers","volume":"7","author":"Wang","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189709_bb0625","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1158\/2159-8290.CD-24-1515","article-title":"Eradicating drug-tolerant persister cells in EGFR-mutated non\u2013small cell lung cancer by targeting TROP2 with CAR-T cellular therapy","volume":"15","author":"Baldacci","year":"2025","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbcan.2026.189709_bb0630","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70090","article-title":"FDA approves second-line TROP2-directed antibody\u2013drug conjugate Dato-DXd for EGFR-mutated NSCLC","volume":"131","author":"Lawrence","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.bbcan.2026.189709_bb0635","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0640","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"6_Supplement","key":"10.1016\/j.bbcan.2026.189709_bb0645","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1158\/1538-7445.AM2024-1882","article-title":"Abstract 1882: DXC024, a novel anti-TROP2\/EGFR bispecific antibody and tubulysin conjugate, for targeted treatment of highly TROP2- or EGFR-expressing tumors","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res."},{"issue":"7_Supplement","key":"10.1016\/j.bbcan.2026.189709_bb0650","doi-asserted-by":"crossref","first-page":"5736","DOI":"10.1158\/1538-7445.AM2023-5736","article-title":"Abstract 5736: AZD9592: an EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond","volume":"83","author":"Comer","year":"2023","journal-title":"Cancer Res."},{"issue":"7_Supplement","key":"10.1016\/j.bbcan.2026.189709_bb0655","doi-asserted-by":"crossref","first-page":"5737","DOI":"10.1158\/1538-7445.AM2023-5737","article-title":"Abstract 5737: evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR\/c-MET targeted bispecific antibody drug conjugate","volume":"83","author":"McGrath","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0660","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of safety of treatment with anti\u2013epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101029","article-title":"Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase IIa trial","volume":"7","author":"Han","year":"2026","journal-title":"Med"},{"issue":"12_Supplement","key":"10.1016\/j.bbcan.2026.189709_bb0670","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1158\/1538-7445.AM2022-5284","article-title":"Abstract 5284: M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression","volume":"82","author":"Knuehl","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0675","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-26-0088","article-title":"ABL209 (NEOK002): Designing an EGFRxMUC1 bispecific TOP1i ADC with promising anti-tumor activity and enhanced therapeutic window","author":"Lee","year":"2026","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2026.189709_bb0680","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.jtho.2021.04.003","article-title":"Immune checkpoint inhibitors in EGFR-mutated NSCLC: dusk or dawn?","volume":"16","author":"Qiao","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0685","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-20-4650","article-title":"Response to standard therapies and comprehensive genomic analysis for patients with lung adenocarcinoma with EGFR exon 20 insertions","volume":"27","author":"Choudhury","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107933","article-title":"Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen","volume":"195","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bbcan.2026.189709_bb0695","doi-asserted-by":"crossref","first-page":"e859","DOI":"10.1016\/j.cllc.2021.04.009","article-title":"EGFR exon 20 insertion mutations: clinicopathological characteristics and treatment outcomes in advanced non\u2013small cell lung cancer","volume":"22","author":"Leal","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.bbcan.2026.189709_bb0700","doi-asserted-by":"crossref","first-page":"S632","DOI":"10.1016\/j.jtho.2021.01.1152","article-title":"P76.95 brief report: Immunochemotherapy in five patients with EGFR exon 20 insertion advanced lung adenocarcinoma","volume":"16","author":"Peng","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0705","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0710","article-title":"Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I\/II study","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2026.189709_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101160","article-title":"Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer","volume":"8","author":"Rudin","year":"2023","journal-title":"ESMO Open."},{"key":"10.1016\/j.bbcan.2026.189709_bb0720","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jtho.2018.05.015","article-title":"Nivolumab plus Erlotinib in patients with EGFR-mutant advanced NSCLC","volume":"13","author":"Gettinger","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0725","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A molecular and preclinical comparison of the PD-1\u2013targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab","volume":"44","author":"Fessas","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0730","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.lungcan.2020.02.003","article-title":"Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer","volume":"142","author":"Besse","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bbcan.2026.189709_bb0735","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1158\/2767-9764.CRC-24-0107","article-title":"Exploration of immune-modulatory effects of Amivantamab in combination with Pembrolizumab in lung and head and neck squamous cell carcinoma","volume":"4","author":"Lim","year":"2024","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.bbcan.2026.189709_bb0740","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.142843","article-title":"Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC","volume":"7","author":"Tu","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbcan.2026.189709_bb0745","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jtho.2023.02.002","article-title":"Another pirate in the Red Ocean? CD73-targeted therapy in EGFR-mutated NSCLC","volume":"18","author":"Horinouchi","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.bbcan.2026.189709_bb0750","doi-asserted-by":"crossref","first-page":"11505","DOI":"10.1200\/JCO.2017.35.15_suppl.11505","article-title":"Increased CD73 and reduced IFNG signature expression in relation to response rates to anti-PD-1(L1) therapies in EGFR-mutant NSCLC","volume":"35","author":"Streicher","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0755","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jtho.2022.12.021","article-title":"CD73 inhibitor Oleclumab plus Osimertinib in previously treated patients with advanced T790M-negative EGFR-mutated NSCLC: a brief report","volume":"18","author":"Kim","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0760","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006837","article-title":"Bispecific antibody CD73xEGFR more selectively inhibits the CD73\/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR","volume":"11","author":"Ploeg","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbcan.2026.189709_bb0765","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/j.jtho.2024.09.141","article-title":"MA07.04 targeting CD24 enhances the response to third-generation tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer","volume":"19","author":"Liang","year":"2024","journal-title":"J. Thorac. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.bbcan.2026.189709_bb0770","doi-asserted-by":"crossref","first-page":"TPS2691","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2691","article-title":"A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM)","volume":"42","author":"Fu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0775","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-70221-9","article-title":"Dual phagocytosis-checkpoint blockade revitalizes immune surveillance in mouse models of glioblastoma","volume":"17","author":"Ha","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbcan.2026.189709_bb0780","article-title":"CD24 is a promising immunotherapeutic target for enhancing efficacy of third-generation EGFR-TKIs on EGFR-mutated lung cancer","author":"Liang","year":"2026","journal-title":"Cancer Commun."},{"key":"10.1016\/j.bbcan.2026.189709_bb0785","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-27107-9","article-title":"CD46 protects the bladder cancer cells from cetuximab-mediated cytotoxicity","volume":"12","author":"Do","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2026.189709_bb0790","first-page":"1192","article-title":"Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade","volume":"3","author":"Shao","year":"2022","journal-title":"Nat. Can."},{"issue":"3_suppl","key":"10.1016\/j.bbcan.2026.189709_bb0795","doi-asserted-by":"crossref","first-page":"TPS239","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS239","article-title":"A phase 1\/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors, including colorectal cancer: trial in progress update","volume":"42","author":"Segal","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0800","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2024.2315640","article-title":"Impact of antibody architecture and paratope valency on effector functions of bispecific NKp30 x EGFR natural killer cell engagers","volume":"16","author":"Boje","year":"2024","journal-title":"mAbs"},{"key":"10.1016\/j.bbcan.2026.189709_bb0805","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232416077","article-title":"B7-H3\/CD276 inhibitors: is there room for the treatment of metastatic non-small cell lung cancer?","volume":"23","author":"Malapelle","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2026.189709_bb0810","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody\u2013drug conjugate in advanced solid tumors: a phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat. Med."},{"issue":"7_Supplement","key":"10.1016\/j.bbcan.2026.189709_bb0815","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1158\/1538-7445.AM2023-558","article-title":"Abstract 558: EGFR inhibition in lung adenocarcinoma upregulates cell surface expression of the placental antigen ALPP and enhances efficacy of ALPP-ADC therapy","volume":"83","author":"Chen","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2026.189709_bb0820","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1190379","article-title":"Cytokine release syndrome and cancer immunotherapies \u2013 historical challenges and promising futures","volume":"14","author":"Shah","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0825","first-page":"239","article-title":"Antibody\u2013drug conjugates in cancer and beyond: progress, promise, and perspectives","volume":"8","author":"Goldmacher","year":"2025","journal-title":"Antib. Ther."},{"key":"10.1016\/j.bbcan.2026.189709_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104858","article-title":"Antibody-oligonucleotide conjugates in cancer therapy: potential and promise","volume":"215","author":"Meng","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbcan.2026.189709_bb0835","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.7150\/thno.102531","article-title":"A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.bbcan.2026.189709_bb0840","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-021-01075-5","article-title":"Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies","volume":"14","author":"Heidbuechel","year":"2021","journal-title":"J. Hematol. Oncol."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X26001812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T19:44:37Z","timestamp":1791056677000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X26001812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":168,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0304419X26001812"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189709","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody therapeutics: A new era for EGFR-mutant NSCLC treatment","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2026.189709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"189709"}}